Von Hoff DD - Search Results

1

Antitumor activity and murine pharmacokinetics of parenteral acronycine.

Dorr RT, Liddil JD, Von Hoff DD, Soble M, Osborne CK. Dorr RT, et al. Among authors: von hoff dd. Cancer Res. 1989 Jan 15;49(2):340-4. Cancer Res. 1989. PMID: 2910453

2

Phase II study of L-alanosine (NSC 153353) in patients with advanced breast cancer. A Southwest Oncology Group study.

Von Hoff DD, Green SJ, Neidhart JA, Fabian C, Budd T, Boyd JF, Osborne CK. Von Hoff DD, et al. Invest New Drugs. 1991 Feb;9(1):87-8. doi: 10.1007/BF00194553. Invest New Drugs. 1991. PMID: 2026487 Clinical Trial. No abstract available.

3

Phase I and clinical pharmacology trial of 502U83 using a monthly single dose schedule.

Von Hoff DD, Kuhn JG, Havlin KA, Langevin AM, Brown TD, Weiss GR, Turner JN, Purvis J, Lucas VS, Bair KW, et al. Von Hoff DD, et al. Cancer Res. 1990 Dec 1;50(23):7496-500. Cancer Res. 1990. PMID: 2253197

4

Endocrine therapy testing of human breast cancers in the soft agar clonogenic assay.

Osborne CK, Von Hoff DD, Mullins K. Osborne CK, et al. Among authors: von hoff dd. Breast Cancer Res Treat. 1985;6(3):229-35. doi: 10.1007/BF01806773. Breast Cancer Res Treat. 1985. PMID: 2936413

5

A radiometric method for evaluation of chemotherapy sensitivity: results of screening a panel of human breast cancer cell lines.

Arteaga CL, Forseth BJ, Clark GM, Von Hoff DD. Arteaga CL, et al. Among authors: von hoff dd. Cancer Res. 1987 Dec 1;47(23):6248-53. Cancer Res. 1987. PMID: 3119196

6

Transforming growth factor beta: potential autocrine growth inhibitor of estrogen receptor-negative human breast cancer cells.

Arteaga CL, Tandon AK, Von Hoff DD, Osborne CK. Arteaga CL, et al. Among authors: von hoff dd. Cancer Res. 1988 Jul 15;48(14):3898-904. Cancer Res. 1988. PMID: 3164252

7

Immunoreactive alpha transforming growth factor activity in effusions from cancer patients as a marker of tumor burden and patient prognosis.

Arteaga CL, Hanauske AR, Clark GM, Osborne CK, Hazarika P, Pardue RL, Tio F, Von Hoff DD. Arteaga CL, et al. Among authors: von hoff dd. Cancer Res. 1988 Sep 1;48(17):5023-8. Cancer Res. 1988. PMID: 3165707

8

Alteration of EGF-receptor binding in human breast cancer cells by antineoplastic agents.

Hanauske AR, Osborne CK, Chamness GC, Clark GM, Forseth BJ, Buchok JB, Arteaga CL, Von Hoff DD. Hanauske AR, et al. Among authors: von hoff dd. Eur J Cancer Clin Oncol. 1987 May;23(5):545-51. doi: 10.1016/0277-5379(87)90318-x. Eur J Cancer Clin Oncol. 1987. PMID: 3498632

9

A randomized trial of doxorubicin, mitoxantrone and bisantrene in advanced breast cancer (a South West Oncology Group Study).

Cowan JD, Osborne CK, Neidhart JA, Von Hoff DD, Constanzi JJ, Vaughn CB. Cowan JD, et al. Among authors: von hoff dd. Invest New Drugs. 1985;3(2):149-52. doi: 10.1007/BF00174162. Invest New Drugs. 1985. PMID: 3894277 Clinical Trial.

10

Mitoxantrone: modest activity in a phase II trial in advanced prostate cancer.

Osborne CK, Drelichman A, Von Hoff DD, Crawford ED. Osborne CK, et al. Among authors: von hoff dd. Cancer Treat Rep. 1983 Dec;67(12):1133-5. Cancer Treat Rep. 1983. PMID: 6652630

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

773 results

Search Page

Filters